KIT Suppresses BRAF^V600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• The receptor tyrosine kinase KIT is crucial for melanocyte development and survival.
• KIT hyperactivity drives melanoma formation, particularly rare types on volar and mucosal surfaces.
• Common melanomas on sun-exposed skin, driven by BRAF/NRAS mutations, paradoxically show reduced KIT expression.

Purpose of the Study:

• To investigate the role of KIT loss in the tumorigenesis of common melanomas.
• To determine if KIT loss facilitates melanoma development and progression.
• To elucidate the interaction between KIT signaling and the RAS/MAPK pathway in melanoma.

Main Methods:

• Introduction of a hypomorphic KIT mutation (kit(lf)) into a BRAF-driven zebrafish melanoma model.
• Analysis of melanoma onset, invasiveness, and RAS/MAPK pathway activation in genetically modified zebrafish.
• KIT knockdown experiments in BRAF V600E-mutant human melanoma cell lines.
• Investigation of wild-type BRAF's role in modulating oncogenic signaling.

Main Results:

• Melanoma onset was accelerated in kit(lf); Tg(mitfa:BRAF) zebrafish.
• Tumors from kit(lf) zebrafish exhibited increased invasiveness and elevated RAS/MAPK pathway activation.
• KIT knockdown in human melanoma cells also increased RAS/MAPK pathway activation.
• Wild-type BRAF was necessary to dampen oncogenic BRAF V600E signaling, a process dependent on KIT expression.

Conclusions:

• Loss of KIT expression can promote melanoma development and invasiveness.
• KIT signaling, potentially through wild-type RAF proteins, can act as a brake on oncogenic BRAF V600E-driven melanoma.
• These findings suggest a complex interplay between KIT and BRAF in melanoma pathogenesis.